Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ANTA PHAR       

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Anthera Pharmaceuticals Inc : Faruqi & Faruqi, LLP is Investigating Anthera Pharmaceuticals Incorporated on Behalf of its Shareholders - ANTH

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/13/2013 | 02:05pm CEST

NEW YORK, Feb. 13, 2013 /PRNewswire/ -- Faruqi & Faruqi, LLP, a national law firm concentrating on investor rights, consumer rights and the enforcement of federal antitrust laws, is investigating potential claims against the board of directors of Anthera Pharmaceuticals Incorporated ("Anthera" or the "Company") (Nasdaq: ANTH) concerning possible breaches of fiduciary duty and other violations of law related to the Company's compensation packages for its executive officers. The investigation focuses on the approval and awarding of certain stock options to executives that may have violated the Company's compensation plans.

(Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO)

Request more information now by clicking here: www.faruqilaw.com/ANTH

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action and derivative litigation. The firm is focused on providing exemplary legal services in the areas of securities, shareholder, antitrust and consumer litigation, through all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients.

If you hold ANTH shares and you would like to discuss your legal rights, visit www.faruqilaw.com/ANTH. You can also contact us by calling Michael J. Hynes free at 877-247-4292 or at 215-277-5770 or by sending an e-mail to mhynes@faruqilaw.com.

Contact:

Faruqi & Faruqi, LLP
Michael J. Hynes, Esq.
101 Greenwood Avenue Suite 600
Jenkintown, PA 19046
Telephone: (877) 247-4292 or (215) 277-5770
E-mail: mhynes@faruqilaw.com

(Nasdaq: ANTH)

Attorney Advertising. (C) 2013 Faruqi & Faruqi, LLP. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ANTA PHAR
08/17 ANTHERA PHARMACEUTICALS : Announces Positive DSMB Review in Phase 3 SOLUTION Stu..
08/16 ANTHERA PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financi..
08/16 Anthera Pharmaceuticals Announces Appointment of Dr. William Shanahan Jr. as ..
08/16 Anthera Pharmaceuticals Announces Positive DSMB Review in Phase 3 SOLUTION St..
08/09 ANTHERA PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fin..
08/09 ANTHERA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
08/09 ANTHERA PHARMACEUTICALS : reports 2Q loss
08/09 Anthera Pharmaceuticals Provides Business Update and Reports 2016 Second Quar..
08/03 Anthera Pharmaceuticals Announces Completion of Dosing in CHABLIS-SC1 Phase 3..
08/02 ANTHERA PHARMACEUTICALS : Biotechnology Stocks on Investors' Radar -- Minerva Ne..
More news
Sector news : Bio Therapeutic Drugs
09:29aDJSANOFI : Regeneron Announce Positive Trials for Cholesterol Drug
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
More sector news : Bio Therapeutic Drugs